Business context and reporting period
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing CNS treatments. This Form 10-Q covers the three and six months ended September 30, 2019 (the company’s fiscal second quarter and first half of fiscal 2020); comparisons are to the corresponding 2018 periods. Its lead programs are AV-101 for major depressive disorder (MDD) and other indications, PH94B for social anxiety disorder (SAD), and PH10 for MDD. The company had no approved products or recurring product revenue.
Financial performance and position
| Metric | Three months ended Sept. 30, 2019 | Six months ended Sept. 30, 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.205 million | $8.519 million |
| General and administrative expense | $1.146 million | $3.056 million |
| Net loss | $5.336 million | $11.546 million |
| Net loss attributable to common stockholders | $5.650 million | $12.162 million |
| Loss per common share, basic and diluted | $0.13 | $0.29 |
- For the six months, operating cash outflow was $8.898 million, compared with $7.063 million in the prior-year period. Investing cash flow was zero; financing cash outflow was $0.130 million. Cash decreased $9.028 million to $4.072 million.
- At September 30, 2019, current assets were $4.677 million and current liabilities $4.117 million. Total liabilities were $12.366 million, including $4.169 million of operating lease obligations and $0.159 million of current notes payable. Stockholders’ equity was a deficit of $3.630 million.
- No meaningful operating margin is reported because the company had no revenue. Research and development represents its principal operating expense.
Material changes versus the prior comparable period
- Second-quarter operating expenses fell to $5.351 million from $7.432 million, and net loss narrowed to $5.336 million from $7.435 million. The main comparison benefit was the absence of a $2.25 million noncash charge in 2018 for the PH94B license and PH10 option. G&A also declined, partly reflecting lower compensation and stock-based compensation expense.
- First-half operating expenses were nearly flat at $11.575 million versus $11.642 million, while net loss improved slightly to $11.546 million from $11.650 million. R&D rose to $8.519 million from $8.005 million as AV-101, PH94B and PH10 development costs increased; this more than offset the nonrecurrence of the prior-year license charge. G&A declined to $3.056 million from $3.637 million.
- First-half operating cash use increased by $1.835 million year over year, and period-end cash was $4.072 million versus $7.832 million at September 30, 2018.
- Adoption of lease accounting on April 1, 2019 recognized a $3.750 million right-of-use asset and $4.169 million operating lease liability at September 30. This accounting change increased reported balance-sheet assets and liabilities; the company assumed exercise of a five-year lease extension.
Outlook, risks and unusual items
- Funding and going concern: Management said cash, including the subsequent $0.600 million private-placement proceeds, was probably insufficient to fund planned operations for the twelve months following issuance of the financial statements without additional financing. The shortfall raises substantial doubt about the company’s ability to continue as a going concern. Management expects to seek equity financing and may pursue collaborations, grants or licensing arrangements; none is assured.
- Development outlook: The final patient in the AV-101 ELEVATE Phase 2 study was dosed at the end of September; management expected top-line results by year-end 2019. PH94B was being prepared for pivotal Phase 3 development, and PH10 Phase 2b development was planned for late 2020. These are forward-looking plans, not assured outcomes.
- Post-period financing and dilution: Between October 30 and November 6, 2019, the company sold 600,000 common-stock units for $0.600 million and issued warrants for 300,000 additional shares at $2.00 per share. The warrants are not exercisable until six months and one day after issuance. The company’s Form S-3 registration statement became effective October 7, subject to restrictions, and could support additional equity sales.
- Key risks: Clinical results and regulatory approval are uncertain; the company relies on third parties for trials and manufacturing; additional capital may be unavailable or dilutive; and competition, intellectual-property challenges, and future commercialization requirements could impair prospects. The filing reports no legal proceedings and no off-balance-sheet arrangements.
- Controls and unusual items: Management concluded disclosure controls were effective, but previously identified material weaknesses in financial-reporting controls—segregation of duties and accounting-software functionality—remained unremediated. First-half expenses also include stock-based compensation and accrued Series B preferred dividends; the Series B dividend rate is 10%.
Most important facts for investors to verify
- Whether ELEVATE results were reported as expected and whether they support further AV-101 development.
- Available cash, actual operating cash burn, financing completed after the filing, and the resulting runway and dilution.
- Timing, funding and clinical/regulatory requirements for PH94B Phase 3 and PH10 Phase 2b plans.
- Whether management’s going-concern assessment changes and whether the identified internal-control weaknesses are remediated.
- Potential share dilution from outstanding preferred stock, options and warrants; the filing reported 21,242,954 warrants outstanding at September 30, 2019.